Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...
A global group of experts has suggested a new approach to diagnosing and treating obesity that does not rely solely on the much-contested body mass index (BMI).
By coincidence (they started before GLP -1 drugs were approved for slimming), a group of 56 doctors have just answered that ...
Body Mass Index, or BMI, has long been criticized as an unreliable method for measuring obesity — and now a group of experts ...
Our reframing acknowledges the nuanced reality of obesity and allows for personalized care,” said Dr. Francesco Rubino of ...
The Lancet Diabetes & Endocrinology published its Commission on the definition and diagnostic criteria of clinical obesity.
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.